The Colorado thyroid disease prevalence study

被引:1857
作者
Canaris, GJ
Manowitz, NR
Mayor, G
Ridgway, EC
机构
[1] Univ Nebraska, Med Ctr, Dept Med, Div Gen Internal Med, Omaha, NE USA
[2] Knoll Pharmaceut Co, Mt Olive, NJ USA
[3] Univ Colorado, Hlth Sci Ctr, Dept Med, Div Endocrinol Diabet & Metab, Denver, CO USA
关键词
D O I
10.1001/archinte.160.4.526
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Context: The prevalence of abnormal thyroid function in the United States and the significance of thyroid dysfunction remain controversial. Systemic effects of abnormal thyroid function hare not been fully delineated, particularly in cases of mild thyroid failure. Also, the relationship between traditional hypothyroid symptoms and biochemical thyroid function is unclear. Objective: To determine the prevalence of abnormal thyroid Function and the relationship between (1) abnormal thyroid Function and lipid levels and (2) abnormal thyroid function and symptoms using modern and sensitive thyroid tests. Design: Cross-sectional study. Participants: Participants in a statewide health fair in Colorado, 1995 (N = 25 862). Main Outcome Measures: Serum thyrotropin (thyroid stimulating hormone [TSH]) and total thyroxine (T-4) concentrations, serum lipid levels, and responses to a hypothyroid symptoms questionnaire. Results: The prevalence of elevated TSH levels (normal range, 0.3-5.1 mlU/L) in this population was 9.5%, and the prevalence of decreased TSH levels was 2.2%. Forty percent of patients taking thyroid medications had abnormal TSH levels. Lipid levels increased in a graded fashion as thyroid function declined. Also, the mean total cholesterol and low-density lipoprotein cholesterol levels of subjects with TSH values between 5.1 and 10 mlU/L were significantly greater than the corresponding mean lipid levels in euthyroid subjects. Symptoms were reported more often in hypothyroid vs euthyroid individuals, but individual symptom sensitivities were low. Conclusions: The prevalence of abnormal biochemical thyroid function reported here is substantial and confirms previous reports in smaller populations. Among patients taking thyroid medication, only 60% were within the normal range of TSH. Modest elevations of TSH corresponded to changes in Lipid levels that may affect cardiovascular health. Individual symptoms were not very sensitive, but patients who report multiple thyroid symptoms warrant serum thyroid testing. These results confirm that thyroid dysfunction is common, may often go undetected, and may be associated with adverse health outcomes that can be avoided by serum TSH measurement.
引用
收藏
页码:526 / 534
页数:9
相关论文
共 52 条
[1]
OKLAHOMA STATE HEALTH DEPARTMENT MOBILE MULTIPHASIC SCREENING PROGRAM FOR CHRONIC DISEASE - .1. [J].
ADLER, JJ ;
BLOSS, CM ;
MOSLEY, KT .
AMERICAN JOURNAL OF PUBLIC HEALTH AND THE NATIONS HEALTH, 1966, 56 (06) :918-&
[2]
LDL/HDL-CHANGES IN SUBCLINICAL HYPOTHYROIDISM - POSSIBLE RISK-FACTORS FOR CORONARY HEART-DISEASE [J].
ALTHAUS, BU ;
STAUB, JJ ;
RYFFDELECHE, A ;
OBERHANSLI, A ;
STAHELIN, HB .
CLINICAL ENDOCRINOLOGY, 1988, 28 (02) :157-163
[3]
Effect of L-thyroxine therapy on lipoprotein fractions in overt and subclinical hypothyroidism, with special reference to lipoprotein(a) [J].
Arem, R ;
Escalante, DA ;
Arem, N ;
Morrisett, JD ;
Patsch, W .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1995, 44 (12) :1559-1563
[4]
LIPOPROTEIN AND APOLIPOPROTEIN LEVELS IN SUBCLINICAL HYPOTHYROIDISM - EFFECT OF LEVOTHYROXINE THERAPY [J].
AREM, R ;
PATSCH, W .
ARCHIVES OF INTERNAL MEDICINE, 1990, 150 (10) :2097-2100
[5]
COMPOSITION OF LOW-DENSITY LIPOPROTEIN AND VERY-LOW-DENSITY LIPOPROTEIN SUBFRACTIONS IN PRIMARY HYPO-THYROIDISM AND THE EFFECT OF HORMONE-REPLACEMENT THERAPY [J].
BALLANTYNE, FC ;
EPENETOS, AA ;
CASLAKE, M ;
FORSYTHE, S ;
BALLANTYNE, D .
CLINICAL SCIENCE, 1979, 57 (01) :83-88
[6]
BILLEWICZ WZ, 1969, Q J MED, V38, P255
[7]
CONTROL OF ADRENERGIC OVERACTIVITY BY BETA-BLOCKADE IMPROVES THE QUALITY-OF-LIFE IN PATIENTS RECEIVING LONG-TERM SUPPRESSIVE THERAPY WITH LEVOTHYROXINE [J].
BIONDI, B ;
FAZIO, S ;
CARELLA, C ;
SABATINI, D ;
AMATO, G ;
CITTADINI, A ;
BELLASTELLA, A ;
LOMBARDI, G ;
SACCA, L .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1994, 78 (05) :1028-1033
[8]
CARDIAC EFFECTS OF LONG-TERM THYROTROPIN-SUPPRESSIVE THERAPY WITH LEVOTHYROXINE [J].
BIONDI, B ;
FAZIO, S ;
CARELLA, C ;
AMATO, G ;
CITTADINI, A ;
LUPOLI, G ;
SACCA, L ;
BELLASTELLA, A ;
LOMBARDI, G .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1993, 77 (02) :334-338
[9]
Bletzer K V, 1989, J Community Health, V14, P149, DOI 10.1007/BF01324364
[10]
SUBCLINICAL HYPOTHYROIDISM AND HYPERLIPOPROTEINEMIA - INDISCRIMINATE L-THYROXINE TREATMENT NOT JUSTIFIED [J].
BOGNER, U ;
ARNTZ, HR ;
PETERS, H ;
SCHLEUSENER, H .
ACTA ENDOCRINOLOGICA, 1993, 128 (03) :202-206